[go: up one dir, main page]

CN111450049B - A kind of preparation method of micron hydrogel with colon-specific delivery - Google Patents

A kind of preparation method of micron hydrogel with colon-specific delivery Download PDF

Info

Publication number
CN111450049B
CN111450049B CN202010395348.0A CN202010395348A CN111450049B CN 111450049 B CN111450049 B CN 111450049B CN 202010395348 A CN202010395348 A CN 202010395348A CN 111450049 B CN111450049 B CN 111450049B
Authority
CN
China
Prior art keywords
puerarin
hydrogel
micro
colon
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010395348.0A
Other languages
Chinese (zh)
Other versions
CN111450049A (en
Inventor
袁彪
程摇蓝
曹崇江
程抒劼
王志祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN202010395348.0A priority Critical patent/CN111450049B/en
Publication of CN111450049A publication Critical patent/CN111450049A/en
Application granted granted Critical
Publication of CN111450049B publication Critical patent/CN111450049B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种具有结肠特异性递送的微米水凝胶制备方法,该将葛根素和低甲氧基果胶溶解于去离子水中,搅拌溶解静置去除气泡后用微流控装置水相进样器吸入,油相进样器吸入溶解有司盘80的矿物油,微流控装置切割产生的油包水微米水凝胶由出样口流出后进入含有无水醋酸锌的壳聚糖溶液中,使果胶溶液破乳后与壳聚糖/醋酸锌交联。将微米水凝胶用于葛根素的包埋与释放。该方法制备的微米水凝胶具有结肠特异性释放的作用。

Figure 202010395348

The invention discloses a method for preparing micron hydrogel with colon-specific delivery. The method comprises dissolving puerarin and low methoxy pectin in deionized water, stirring, dissolving and standing to remove air bubbles, and then using a microfluidic device to water phase The sampler inhales, the oil-phase injector inhales the mineral oil dissolved with Span 80, and the water-in-oil micro-hydrogel produced by the cutting of the microfluidic device flows out of the sample outlet and enters the chitosan solution containing anhydrous zinc acetate. , the pectin solution was demulsified and cross-linked with chitosan/zinc acetate. Micron hydrogels were used for entrapment and release of puerarin. The micro-hydrogel prepared by this method has the effect of colon-specific release.

Figure 202010395348

Description

Preparation method of micro hydrogel with colon-specific delivery
Technical Field
The invention relates to a preparation method of hydrogel, in particular to a preparation method of micro hydrogel with colon-specific delivery.
Background
Puerarin has good treatment effect on colon cancer and colitis clinically, but direct oral administration has great influence on the activity of digestive enzyme in gastrointestinal tract.
The low methoxyl pectin used as colon targeting drug carrier has great superiority, and can be specifically hydrolyzed by pectinase produced by colon intestinal flora, thereby protecting the drug from releasing in gastrointestinal tract. Pectin is a polygalacturonic acid polysaccharide, and low methoxyl pectin is generally produced from plant material containing high ester pectin, and the esterification degree is lower than 50%. Pectin is widely used in cosmetics, foods and pharmaceutical preparations, and has no toxicity, so it can be used for oral administration.
Microfluidics provides a novel approach to hydrogel preparation and research. The microchip is made of polydimethylsiloxane and comprises three parts: two cross-shaped junctions, three sample channels and a wider merged channel. A water-in-oil droplet is formed at the cross-shaped junction where the continuous phase and the dispersed phase intersect, and the droplet is collected into the chitosan solution after passing through the merging channel. The chitosan solution containing the droplets is gently stirred to break up the water-in-oil droplets, and then pectin and chitosan are crosslinked into the micro hydrogel through electrostatic interaction.
Disclosure of Invention
The purpose of the invention is as follows: the invention aims to provide a preparation method of a micro hydrogel with colon-specific delivery.
The technical scheme is as follows: the invention provides a preparation method of a micro hydrogel with colon-specific delivery, which comprises the following steps:
(1) placing puerarin in sterile distilled water, stirring to completely dissolve to obtain puerarin solution, then placing low methoxyl pectin in puerarin solution, stirring to hydrate to obtain puerarin-containing low methoxyl pectin water solution, standing to remove bubbles;
(2) adding span 80 into mineral oil, stirring, and standing overnight to remove bubbles;
(3) adding chitosan into an aqueous solution containing glacial acetic acid, stirring until the chitosan is completely dissolved, and adding a cross-linking agent to prepare a chitosan solution containing zinc acetate;
(4) sucking the puerarin-containing low methoxyl pectin aqueous solution obtained in the step (1) into a water phase sample injector of a microfluidic system, sucking the mineral oil obtained in the step (2) into an oil phase sample injector of the microfluidic system, and regulating the particle size of the micro hydrogel by controlling the speed of the water phase and the oil phase;
(5) and (4) dropwise adding the water-in-oil solution obtained in the step (4) into the chitosan solution obtained in the step (3), and stirring at a low speed to prepare the puerarin-containing pectin-chitosan-cross-linking agent micro hydrogel.
Further, the cross-linking agent is zinc acetate.
Further, the main structure of the chip in the microfluidic system comprises an upper layer substrate and a lower layer substrate.
Furthermore, the upper and lower substrates are made of polydimethylsiloxane and glass materials respectively.
Further, the concentration of the chitosan is 0.2%, 0.4% or 0.6%.
Further, the concentration of the low methoxyl pectin aqueous solution is 0.5%, 1%, 2%, 4% or 6%.
Further, the micro-hydrogel delivers puerarin specifically at the colon site.
Has the advantages that: (1) the pectin and the chitosan are used as main raw materials, are natural polysaccharides, have good biocompatibility and degradability, and can meet the requirements of oral materials; (2) pectin and chitosan are resistant to enzymes in the stomach and intestinal tract, but are specifically degraded by enzymes produced by the colonic flora, making pectin and chitosan based delivery systems the most suitable choice for colon specific delivery; (3) the invention adopts the microfluid technology and provides a new innovative method for the preparation and research of the hydrogel. The prepared micro hydrogel with uniform particle size stably exists in the gastrointestinal tract and is slowly degraded in the colon, so that the micro hydrogel is the best choice for colon-specific delivery; (4) the invention loads and releases puerarin with anti-colon cancer effect, and the result shows that the micro hydrogel not only has slow release effect, but also can reduce the inhibition effect of the puerarin on the enzymatic activity of protease with digestive effect in gastrointestinal tract.
Drawings
FIG. 1 is a schematic diagram of the working principle of the microfluidic system according to the present invention;
FIG. 2 shows the results of the inhibition of colon cancer cells (HCT116) by puerarin and the biocompatibility test of macrophages (RAW 264.7);
FIG. 3 is the experimental result of the effect of puerarin on the spatial structure of pepsin and trypsin;
FIG. 4 is a graph showing the effect of zinc acetate on the optimal pectin concentration for forming a hydrogel according to the present invention;
FIG. 5 is a graph showing the effect of chitosan concentration on hydrogel swelling performance and particle size and potential test of unloaded and puerarin-loaded micro hydrogel;
FIG. 6 is a graph showing the encapsulation efficiency of the hydrogel for puerarin according to the present invention;
FIG. 7 is a graph showing the results of the stability of the puerarin-encapsulated micro-hydrogel in normal saline, simulated gastrointestinal tract and simulated colon;
FIG. 8 is a graph of infrared spectroscopy and thermogravimetric analysis of a hydrogel of the invention;
FIG. 9 is a transmission electron micrograph of a micro hydrogel of the present invention.
Detailed Description
Experimental materials:
puerarin is purchased from energy chemical industry (purity 98%; Shanghai, China). Food-grade low-methoxyl pectin (dry basis is more than or equal to 74.0 percent), sorbitan monooleate (CAS: 1338-43-8), paraffin liquid (CAS: 8012-95-1), pectinase (CAS: 9032-75-1, 30000U/g) and chitosan (more than or equal to 95 percent deacetylation, viscosity 100-. Zinc acetate was purchased from alatin (99% pure; shanghai, china). Chitosanase was purchased from Yuye Biotechnology, Inc. (Shanghai). Dimethyl sulfoxide (DMSO), 3- (4, 5-dimethyl-2-thiazolyl) -2, 5-diphenyl-2H-tetrazolium bromide (MTT) was obtained from Sigma-Aldrich (St. Louis, Mo.).
Example 1: functional activity, biocompatibility and influence on protease structure of puerarin.
(1) Colon cancer cells (HCT116 cells) in logarithmic growth phase were digested, counted, adjusted to initial cell concentrations of 1000/well and 2000/well, seeded into 96-well plates, respectively, and placed in 5% CO2Culturing in incubator for 24 hr, preparing puerarin into 25, 50, 100, 200, 400, 800 μ g/mL solution, and filtering with 0.22 μm water system filter membrane. And (3) sucking out the cell supernatant culture solution of the 96-well plate by using a pipette gun, adding the puerarin solution into a blank group which is a blank complete culture medium without the puerarin solution, continuously culturing the cells, and detecting the cell activity by using an MTT method after culturing for 72h and 48h respectively. The obtained cell survival rates are respectively shown in (a) and (b) in fig. 2, wherein the results of the (a) graph show that the initial concentration of HCT116 cells is 1000/hole, and when the cells are cultured for 72 hours, the higher the puerarin concentration is, the higher the cell inhibition rate is, so that the puerarin has a better colon cancer inhibition effect; (b) the results of the graphs show that the initial concentration of HCT116 cells is 2000 cells/hole, and the cell inhibition rate is increased along with the higher concentration of puerarin when the cells are cultured for 48 hours, which indicates that the puerarin also has higher contentGood colon cancer inhibiting effect. Therefore, it can be said that puerarin is a substance having a good colon cancer inhibitory activity.
(2) Collecting RAW264.7 in logarithmic growth phase, counting, and adjusting initial concentration of cells to 50 × 104one/mL, inoculated into 96-well plates, respectively, and placed in 5% CO2Culturing in incubator for 24 hr, preparing puerarin into 25, 50, 100, 200, 400, 800 μ g/mL solution, and filtering with 0.22 μm water system filter membrane. And (3) sucking out the cell supernatant culture solution of the 96-well plate by using a pipette gun, adding the puerarin solution into the culture solution, continuously culturing the cells by using a blank complete culture medium without the puerarin solution, and detecting the cell activity by using an MTT (methanol to transfer) method after culturing for 24 hours to obtain the cell survival rate. As shown in (c) and (d) of FIG. 2, the results of (c) are that the cell viability under the action of high concentration puerarin is higher than 90% at the absorbance value of 490nm of the detection wavelength, which indicates that puerarin has good biocompatibility; (d) the results of the graphs show that the cell survival rate under the action of high-concentration puerarin is similar to that of a blank control group without puerarin and is higher than 90 percent at the light absorption value of reference wavelength of 570nm, which indicates that the puerarin has good biocompatibility.
(3) Trypsin solution (2.0mL, 0.2mM) was added to each 5mL centrifuge tube at room temperature, and then 0, 10, 20, 30, 40 and 50. mu. L1.0mM puerarin solutions were added to the centrifuge tubes. After adding puerarin solution, mixing the mixture uniformly, and scanning absorption spectrum at 200nm-350nm with ultraviolet spectrophotometer after 2 minutes to obtain ultraviolet absorption difference spectrum of trypsin under action of puerarin with gradient concentration as shown in (a) in figure 3. And the emission spectrum of trypsin at 300-450nm under the action of puerarin with gradient concentration as shown in (c) in FIG. 3 is obtained by detecting with a fluorescence spectrophotometer under the excitation wavelength of λ ex-295 nm. Similar to the trypsin assay, the pepsin solution (2.0mL, 0.5X 10) was aspirated-2mM) was placed in a centrifuge tube, followed by addition of puerarin solution and uniform mixing. Scanning the absorption spectrum at 200-300nm with a UV spectrophotometer after 2 minutes to obtain the UV absorption difference spectrum of pepsin under the action of graded concentration puerarin as shown in (b) in FIG. 3, and obtaining the absorption difference spectrum at λ ex ═ 295 and λ ex-Fluorescence emission spectra of pepsin at 300-450nm under the action of graded concentration puerarin are respectively detected as (d) and (e) in fig. 3 at an excitation wavelength of 278 nm. The ultraviolet absorption spectrum and fluorescence spectrum results show that puerarin has influence on the space structures of trypsin and pepsin, and the influence is more obvious as the concentration of the puerarin is increased.
Example 2: preparation of the micro-hydrogels
(1) Puerarin was put in sterile distilled water and stirred until completely dissolved to prepare a puerarin solution (800. mu.g/mL). Then, adding low methoxyl pectin into puerarin solution, stirring until completely hydrated to prepare continuous phase, and standing to remove bubbles after low methoxyl pectin is completely hydrated. The chitosan solution was prepared by placing chitosan in an acetic acid solution (1% w/v) to dissolve it completely. Zinc acetate was added to the chitosan solution and stirred for 2 hours to prepare a chitosan solution containing zinc acetate (5% w/v). Sorbitol monooleate (1% w/v) was added to liquid paraffin and stirred for 2 hours, and then left overnight to remove air bubbles for preparing a dispersed phase. All experiments were performed at room temperature.
(2) The continuous phase and the dispersed phase are injected into the microfluidic chip by using a pressure system, the flow is controlled by using a flow sensor, the flow sensor is connected onto the chip by a syringe and a fused silica capillary, and the size of the gel can be adjusted by controlling the speed of the continuous phase and the dispersed phase. Unless otherwise stated, the continuous phase flow rate was 2. mu.L/min, the dispersed phase flow rate was 20. mu.L/min, and the resulting droplet diameter was about 100. mu.m. The chip holder was used to place the chip under an optical microscope. Images were recorded at the inlet and outlet of the cruciform junction, coalescence channel. (the micro-fluidic system comprises a dispersed phase inlet 1, a first continuous phase inlet 2, a second continuous phase inlet 3, a third continuous phase inlet 4, a cross-shaped junction intersection 5 of the dispersed phase and the continuous phase, a merging channel 6, a magnetic stirrer and a beaker 7 arranged on the magnetic stirrer, wherein the dispersed phase cuts the continuous phase to form water-in-oil droplets for collecting samples, the beaker 7 is internally added with a zinc acetate-chitosan solution, and the droplets prepared by the micro-fluidic system are collected and stirred at low speed under the magnetic stirrer so that the droplets are demulsified and then are subjected to electrostatic crosslinking to form micro-hydrogel. the micro-hydrogel is shown in figure 1)
(3) Aqueous solutions of low methoxyl pectin (0.5%, 1%, 2%, 4% and 6%) at different concentrations were cross-linked with chitosan solution containing zinc acetate to form samples, and the resulting particles were washed repeatedly with distilled water until no liquid paraffin was present, and the washed samples were diluted with water. A small amount of sample was pipetted onto the slide, carefully covered with a cover slip, and the morphology of the hydrogel was observed using an inverted microscope equipped with a digital camera. As shown in fig. 4 (a), (b), (c), (d) and (e), 0.5%, 1%, 2%, 4% and 6% of low methoxyl pectin and chitosan solution containing zinc acetate are crosslinked to form micro hydrogel. By comparing the morphology of the micro-hydrogels, the micro-hydrogel morphology of panel (e) was found to be the most stable, thereby determining the optimal pectin concentration value for forming the micro-hydrogels to be 6%. The effect of zinc acetate on the crosslinking result was investigated by crosslinking pectin at optimum concentration with a chitosan solution without zinc acetate. The results show that a morphologically stable micro hydrogel could not be formed, as shown in figure (f). The results show that a 6% pectin solution and a chitosan solution containing zinc acetate can form a stable micro hydrogel.
(4) Different concentrations of chitin solution (0.2%, 0.4% and 0.6%) coated hydrogels were immersed in NaCl solution (0.9%) at 37 ℃ at a rate of 150r/min, the hydrogels were observed microscopically every 1 hour, and size measurements were performed on at least 60 particles using Nano Measurer 1.2 software. By comparing the swelling ratios of the different chitosan-coated micro hydrogels in the range of 37 ℃, the results are shown in fig. 5 (a), and the optimal chitosan concentration of the micro hydrogel is determined to be 0.6%.
(5) Zeta potentials of the hydrogel and the puerarin-loaded hydrogel were measured using a Zetasizer Nano-ZS90 instrument over a pH range of 2.0-11.0, as shown in fig. 5 (d), indicating that the surface of the micro-hydrogel was positively charged. The particle size distributions of the unloaded and puerarin loaded micro hydrogel particles were measured using Nano Measurer 1.2 software, as shown in (b) and (c) of fig. 5, and the results indicate that the particle size of the puerarin loaded micro hydrogel was significantly larger than the unloaded micro hydrogel.
Example 3: research on encapsulation efficiency and stability of hydrogel on puerarin
(1) A standard curve was established using a puerarin standard by High Performance Liquid Chromatography (HPLC), and as shown in fig. 6 (a), it is a liquid chromatogram of the puerarin standard. Pectinase and chitosanase hydrolyze the blank control group and the puerarin-loaded micro hydrogel sample group, and (b) and (c) in fig. 6 are liquid chromatograms of the blank control group and the puerarin-loaded group, respectively. After the hydrogel was completely hydrolyzed, it was filtered through a 0.22 μm filter, and the supernatant was subjected to high performance liquid chromatography to detect the content of puerarin. In the present embodiment, a tube with Tuna C18(2)
Figure GDA0002981889310000051
RP-HPLC system (Agilent1200, Shanghai, China) with a 250X4.6mm column. The column temperature used was 25 ℃ and the ratio of mobile phase methanol to water was 1: 3. The detection wavelength was set at 250nm and the flow rate was 1 mL/min. The sample size was set to 20 μ L. As shown in fig. 6 (d), the result showed that the encapsulation efficiency of the micro hydrogel to puerarin was 54.1%.
(2) To investigate the enzymatic properties of the prepared micro-hydrogels, in vitro release experiments were performed at 37 ℃. The same mass of puerarin loaded micro-hydrogels were incubated in normal saline (0.9% NaCl), simulated gastric fluid (pH 2.2), simulated intestinal fluid (pH 7.2) and simulated colon fluid (containing pectinase and chitosanase) for 6 hours to study the release of the micro-hydrogels in different media, and the puerarin content in the supernatant was determined by RP-HPLC every hour, and each experiment was repeated at least three times. As shown in (a), (b), (c) and (d) of fig. 7, the results indicate that the puerarin-loaded micro hydrogel is relatively stable in physiological saline, simulated gastric fluid and simulated intestinal fluid, and releases a large amount of puerarin in colonic fluid.
(3) To simulate the digestion conditions of the gastrointestinal tract, the puerarin loaded micro-hydrogel was first placed in citric acid buffer (pH 2.2) for 2h to simulate gastric digestion, then transferred to citric acid buffer (pH 7.2) for 6h to simulate small intestine digestion, and finally the pectinase and chitosanase lysates were transferred to citrate buffer for 2h to simulate colonic digestion. The micro-hydrogel was continuously stirred on a constant temperature shaker at 150 rpm. Puerarin release was measured by RP-HPLC for each system every 1 hour, and each experiment was repeated at least three times. As shown in fig. 7 (e), the results showed that puerarin was released in small amounts in stomach and small intestine fluids, and in colon fluids, puerarin was released rapidly in the first hour and then slowly.
Example 4: structural characterization of hydrogels
(1) Fourier Infrared Spectroscopy
A Fourier transform infrared spectrophotometer is used for researching the existence state of puerarin in the pectin-chitosan-zinc acetate micron hydrogel and the interaction force of each component.
The components used for the experiment were prepared by freeze-drying, and the lyophilization process of the micro-hydrogels was performed in a Christ Alpha1-4 lyophilizer (Christ, ALPHA 1-4/2-4LD plus, Shanghai). At 400 to 4000cm-1The FT-IR spectra of puerarin, unloaded hydrogel and loaded hydrogel were obtained in the wavenumber range of (a), and from the results shown in fig. 7, the infrared spectrum of the puerarin-loaded hydrogel did not include the absorption peak of puerarin and coincided with the absorption peak of the unloaded hydrogel, as shown in (a) in fig. 8, it was revealed that puerarin existed in the network structure of the hydrogel in a free state.
To verify the structure of the micro-hydrogels, the thickness of the micro-hydrogels was between 400 and 4000cm-1The FT-IR spectra of the components were obtained in the wavenumber range of (a) to provide information on the nature of the chemical bonds involved in the formation of the micro-hydrogel. As shown in FIG. 7 (b), at 1745cm-1And 1648cm-1The absorption peak is the stretching vibration peak of methoxyl and carboxyl in pectin. The stretching vibration peaks of the amido group, amido bond and amino group of the chitosan are respectively 1554cm-1、1632cm-1And 3216cm-1Is absorbed by the absorption body. At 1553cm-1And 1453cm-1The absorption bands at (a) represent the symmetric and asymmetric tensile vibrations of the carboxyl group in zinc acetate. In this study, the condensation reaction of the amino groups in chitosan with the carboxyl groups in pectin indicated that acetate stabilized water as a cross-linking agent when zinc cross-linkedThe effect of the gel, zinc acetate, is similar to the effect of calcium ions in chitosan/sodium alginate gel. By comparing the Fourier transform infrared spectra of pectin, chitosan, zinc acetate and hydrogel, it was found that the hydrogel spectrum showed 1755cm of pectin-1Stretching vibration peak of methoxy group (2). At 1100--1Nearby a wider absorption band, 1553cm of amine group in zinc can be seen-1Stretching vibration peak and 531cm in zinc acetate-1Zn-O stretching vibration peak of (1). Related to the tensile vibration of CN. As shown in FIG. 8 (b), it was confirmed that the micro hydrogel was formed by electrostatic crosslinking.
(2) Analysis of thermal Properties
Thermogravimetry (TGA) has been widely used to confirm the detected change in thermal stability of hydrogels with temperature. For TGA analysis, hydrogels prepared by microfluidic techniques were placed in centrifuge tubes and centrifuged to remove distilled water and used for experiments. Stability and thermal degradation of the puerarin loaded micro-hydrogels were evaluated using a thermogravimetric analyzer TGA-50 (Shimadzu Corporation, kyoto, japan). First, a sample (10mg) was heated in a platinum pan at a rate of 10 ℃/min under a stream of nitrogen at 40mL/min and analyzed at a temperature of 30 to 150 ℃.
The results show that the weight of the micro hydrogel consisting of pectin-chitosan-zinc acetate decreases with increasing temperature. As shown in fig. 8 (c), when the temperature was increased from 32 ℃ to 120 ℃, the weight changed significantly, and after 120 ℃, the weight hardly changed any more, and the weight loss in this temperature range corresponded to the evaporation of free water, as shown in fig. 8 (c), indicating that the free water content in the micro hydrogel was 94.36%.
(4) Transmission electron microscope
Transmission Electron Microscope (TEM) imaging can provide a great deal of information for hydrogels. The structure of the hydrogel was observed using a CM10 transmission electron microscope (HITACHI, H-9500, Japan). Freshly prepared hydrogels (10 μ L) were deposited on a 3.05mm grid using ultrathin sections (80-100nm gold and silver) and excess water was absorbed with filter paper and air dried for observation. As shown in FIG. 9(a), the micro hydrogels were all spherical structures with more uniform shape and size, as shown in FIG. 9(b), indicating that the micro hydrogels had a dense core and a thin coating. Fig. 9(c) shows that the chitosan-zinc acetate composite coating may be surface polymer chains extending into the aqueous phase and may be considered as a halo of light around the particles. As shown in fig. 9 (d), after digestion in simulated colonic fluid, the spherical micro-hydrogel was hydrolyzed by colonic enzymes. The particle sizes measured by TEM are all smaller than the hydrodynamic particle size collected by dynamic light scattering due to the drying process of TEM sample preparation.

Claims (5)

1.一种具有结肠特异性递送的微米水凝胶制备方法,其特征在于:包括如下步骤:1. a micron hydrogel preparation method with colon specific delivery is characterized in that: comprise the steps: (1)将葛根素置于无菌蒸馏水中,搅拌至完全溶解,制得葛根素溶液,然后,将低甲氧基果胶放入葛根素溶液中搅拌至水化,制得含葛根素的低甲氧基果胶水溶液,静置去除气泡;(1) place puerarin in sterile distilled water, stir until completely dissolved, to obtain puerarin solution, then, put low methoxyl pectin into puerarin solution and stir until hydration, to obtain puerarin-containing Low methoxy pectin aqueous solution, let stand to remove air bubbles; (2)将司盘80加入矿物油后搅拌,静置去除气泡;(2) Stir after adding the mineral oil to the Span 80, and let stand to remove air bubbles; (3)将壳聚糖加入含冰醋酸的水溶液中,搅拌至完全溶解后加入交联剂,制得含醋酸锌的壳聚糖溶液;(3) adding chitosan to the aqueous solution containing glacial acetic acid, stirring until completely dissolved, and then adding a cross-linking agent to prepare a chitosan solution containing zinc acetate; (4)将步骤(1)所得的含葛根素的低甲氧基果胶水溶液吸入微流控系统的水相进样器,将步骤(2)所制得的矿物油吸入微流控系统的油相进样器,通过控制水相和油相的速率来调节水凝胶的粒径;(4) the low methoxyl pectin aqueous solution containing puerarin obtained in step (1) is sucked into the water-phase sampler of the microfluidic system, and the mineral oil obtained in step (2) is sucked into the microfluidic system. Oil phase injector, adjust the particle size of hydrogel by controlling the rate of water phase and oil phase; (5)将步骤(4)所得油包水液滴加入到步骤(3)所得的壳聚糖溶液中,低速搅拌以制得包含葛根素的果胶-壳聚糖-交联剂微米水凝胶。(5) adding water-in-oil droplets obtained in step (4) to the chitosan solution obtained in step (3), and stirring at low speed to prepare pectin-chitosan-crosslinking agent micro-hydrogels containing puerarin glue. 2.根据权利要求1所述的具有结肠特异性递送的微米水凝胶制备方法,其特征在于:所述微流控系统中芯片的主体结构包括上下两层基片。2 . The method for preparing a micro-hydrogel with colon-specific delivery according to claim 1 , wherein the main structure of the chip in the microfluidic system comprises an upper and lower substrate. 3 . 3.根据权利要求2所述的具有结肠特异性递送的微米水凝胶制备方法,其特征在于:所述上下两层基片分别为聚二甲基硅氧烷和玻璃材料。3 . The method for preparing micron hydrogel with colon-specific delivery according to claim 2 , wherein the upper and lower substrates are respectively made of polydimethylsiloxane and glass material. 4 . 4.根据权利要求1所述的具有结肠特异性递送的微米水凝胶制备方法,其特征在于:所述壳聚糖的浓度为0.2%、0.4%或0.6%。4 . The method for preparing micro-hydrogel with colon-specific delivery according to claim 1 , wherein the concentration of the chitosan is 0.2%, 0.4% or 0.6%. 5 . 5.根据权利要求1所述的具有结肠特异性递送的微米水凝胶制备方法,其特征在于:所述低甲氧基果胶水溶液浓度为0.5%、1%、2%、4%或6%。5. The method for preparing micro-hydrogel with colon-specific delivery according to claim 1, wherein the concentration of the low methoxy pectin aqueous solution is 0.5%, 1%, 2%, 4% or 6% %.
CN202010395348.0A 2020-05-11 2020-05-11 A kind of preparation method of micron hydrogel with colon-specific delivery Active CN111450049B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010395348.0A CN111450049B (en) 2020-05-11 2020-05-11 A kind of preparation method of micron hydrogel with colon-specific delivery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010395348.0A CN111450049B (en) 2020-05-11 2020-05-11 A kind of preparation method of micron hydrogel with colon-specific delivery

Publications (2)

Publication Number Publication Date
CN111450049A CN111450049A (en) 2020-07-28
CN111450049B true CN111450049B (en) 2021-06-25

Family

ID=71672307

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010395348.0A Active CN111450049B (en) 2020-05-11 2020-05-11 A kind of preparation method of micron hydrogel with colon-specific delivery

Country Status (1)

Country Link
CN (1) CN111450049B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111991368B (en) * 2020-09-11 2021-11-12 中国药科大学 A kind of preparation method of soybean protein isolate-quaternary ammonium salt chitosan microcapsules coated with tea polyphenols
CN115429929B (en) * 2021-06-04 2024-08-13 中国科学院上海硅酸盐研究所 Injectable self-assembled hydrogel and preparation method and application thereof
CN116019220B (en) * 2023-02-28 2024-05-17 劲牌持正堂药业有限公司 Method for reducing bitterness of radix Puerariae extract and improving water solubility thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257892A (en) * 2005-05-18 2008-09-03 达沃尔泰拉公司 Colonic delivery of sorbents
CN104323985A (en) * 2014-11-07 2015-02-04 郑州大学 Preparation method and applications of carbon material-based polysaccharide oral colon-targeting hydrogel
CN104367588A (en) * 2014-11-29 2015-02-25 山西医科大学 Dexamethasone, pectin and zinc combined gel oral colon-specific drug delivery pellet
KR20190009951A (en) * 2017-07-20 2019-01-30 한서대학교 산학협력단 Colon specific targeted drug delivery agent
CN109662946A (en) * 2019-01-14 2019-04-23 中国药科大学 A kind of device and method and application carrying medicine metal-organic framework materials based on micro-fluidic one pot process
CN109806238A (en) * 2019-03-18 2019-05-28 徐州生物工程职业技术学院 A kind of preparation method of Indomethacin colon drug delivery pellet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040243041A1 (en) * 1994-10-27 2004-12-02 Yimin Qin Wound dressing

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257892A (en) * 2005-05-18 2008-09-03 达沃尔泰拉公司 Colonic delivery of sorbents
CN104323985A (en) * 2014-11-07 2015-02-04 郑州大学 Preparation method and applications of carbon material-based polysaccharide oral colon-targeting hydrogel
CN104367588A (en) * 2014-11-29 2015-02-25 山西医科大学 Dexamethasone, pectin and zinc combined gel oral colon-specific drug delivery pellet
KR20190009951A (en) * 2017-07-20 2019-01-30 한서대학교 산학협력단 Colon specific targeted drug delivery agent
CN109662946A (en) * 2019-01-14 2019-04-23 中国药科大学 A kind of device and method and application carrying medicine metal-organic framework materials based on micro-fluidic one pot process
CN109806238A (en) * 2019-03-18 2019-05-28 徐州生物工程职业技术学院 A kind of preparation method of Indomethacin colon drug delivery pellet

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Colon targeted beads loaded with pterostilbene: Formulation, optimization, characterization and in vivo evaluation;Mudassir Ansari et al;《Saudi Pharmaceutical Journal》;20180720(第27期);第71-81页 *
Development and in vitro/in vivo evaluation of Zn-pectinate microparticles reinforced with chitosan for the colonic delivery of progesterone;Hytham H. Gadalla et al;《Drug Deliv》;20150408;第23卷(第4期);第2541-2554页 *
Preparation and evaluation of zinc–pectin–chitosan composite particles for drug delivery to the colon: Role of chitosan in modifying in vitro and in vivo drug release;Surajit Das et al;《International Journal of Pharmaceutics》;20101217(第406期);第11-20页 *
Prilling for the development of multi-particulate colon drug delivery systems: Pectin vs. pectin–alginate beads;Giulia Auriemma et al;《Carbohydrate Polymers》;20121004(第92期);第367-373页 *
优选大黄总蒽醌结肠定位壳聚糖微球的制备工艺;刘喜纲,等;《中草药》;20150131;第46卷(第1期);第38-42页 *
基于3D打印微流控技术制备海藻酸钙微/纳米凝胶及其载药应用;蔡诗轩;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;20200215;第B014-1226页 *
天然多糖在结肠靶向药物载体中的研究与应用;尚晓娅,等;《化学与生物工程》;20091231;第26卷(第7期);第70-74页 *
微流控技术制备HA微凝胶及其作为细胞载体的应用研究;马婷;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;20180715(第07期);第B014-686页 *
微流控技术制备水凝胶及其靶向递送食品功能活性因子;袁彪;《中国食品科技技术学会第十七届年会摘要集》;20201028;第187-188页 *
果胶-壳聚糖-卵磷脂复合结肠给药系统研究;郭春静;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;20180315(第03期);第B016-420页 *
果胶-壳聚糖聚合物在药物释放系统中的应用进展、;吴丽,等;《现代化工》;20141130;第34卷(第11期);第37-40页 *

Also Published As

Publication number Publication date
CN111450049A (en) 2020-07-28

Similar Documents

Publication Publication Date Title
CN111450049B (en) A kind of preparation method of micron hydrogel with colon-specific delivery
Dastidar et al. Porous microspheres: Synthesis, characterisation and applications in pharmaceutical & medical fields
Günter et al. Calcium pectinate gel beads obtained from callus cultures pectins as promising systems for colon-targeted drug delivery
Wang et al. Preparation of uniform sized chitosan microspheres by membrane emulsification technique and application as a carrier of protein drug
CN114452268B (en) Preparation method of mesoporous polydopamine anthocyanin-carrying nanoparticle
Akyuz et al. A new pollen-derived microcarrier for pantoprazole delivery
Peng et al. Soluble starch–based biodegradable and microporous microspheres as potential adsorbent for stabilization and controlled release of coix seed oil
Bian et al. Preparation and study on anti-tumor effect of chitosan-coated oleanolic acid liposomes
Wang et al. Preparation of core-shell microcapsules based on microfluidic technology for the encapsulation, protection and controlled delivery of phycocyanin
Grama et al. Novel fluorescent poly (glycidyl methacrylate)–Silica microspheres
Luo et al. Microfluidic fabrication of encapsulated probiotic microspheres using cysteine-modified chitosan with dual functions of bacterial adhesion and intestinal mucosal adhesion
Zhang et al. Hepatic-targeting microcapsules construction by self-assembly of bioactive galactose-branched polyelectrolyte for controlled drug release system
Li et al. Dopamine-functionalized hyaluronic acid microspheres for effective capture of CD44-overexpressing circulating tumor cells
Cesur et al. Controlled release of metformin loaded polyvinyl alcohol (PVA) microbubble/nanoparticles using microfluidic device for the treatment of type 2 diabetes mellitus
Li et al. Fabrication and characterization of shellac nanofibers with colon-targeted delivery of quercetin and its anticancer activity
CN113425854A (en) Anisic acid and polyethyleneimine modified tumor-targeted mesoporous silica nanoparticles, and preparation method and application thereof
Enyu et al. Construction and performance evaluation of pH-responsive oxidized hyaluronic acid hollow mesoporous silica nanoparticles
Liu et al. Structure and properties of nanoparticles: DES-lignin-g-PNVCL coated aspirin by self-assembly
Wang et al. Effects of microgels fabricated by microfluidic on the stability, antioxidant, and immunoenhancing activities of aquatic protein
Arya et al. Capturing rare cells from blood using a packed bed of custom-synthesized chitosan microparticles
Bie et al. Characterization of concanavalin A-conjugated resistant starch acetate bioadhesive film for oral colon-targeting microcapsule delivery system
Li et al. Optical sensing properties of Au nanoparticle/hydrogel composite microbeads using droplet microfluidics
CN113288881B (en) Preparation method of pH response type active factor carrier system and application of pH response type active factor carrier system in intestinal targeting
Xu et al. Monodisperse polyaspartic acid derivative microspheres for potential tumor embolization therapy
Elmehbad et al. Green synthesis of nano-silver/sodium alginate/carboxymethyl xanthan gum hydrogel and evaluation of its anti-inflammatory and anti-helicobacter pylori activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant